

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. *N Engl J Med* 2006;354:229-40.

Table 4. Baseline QOL Domain data of the 164 Study Participants *

QOL Tool	Domain	Normal Saline (N = 81)	Hypertonic Saline (N = 83)
SF-36	Physical function	85 ± 16	86 ± 12
	Role -physical	64 ± 40	75 ± 34
	Bodily pain	74 ± 22	81 ± 18
	General health	44 ± 18	46 ± 21
	Vitality	60 ± 20	62 ± 20
	Social function	79 ± 23	79 ± 20
	Role -emotional	88 ± 24	88 ± 24
	Mental health	78 ± 12	78 ± 13
CFQ Adult	Physical	72 ± 22	72 ± 18
	Role	83 ± 24	84 ± 18
	Vitality	60 ± 19	61 ± 16
	Emotional	76 ± 14	77 ± 16
	Social	70 ± 20	74 ± 15
	Body	78 ± 25	79 ± 25
	Eating	83 ± 23	86 ± 25
	Burden	58 ± 22	62 ± 17
	Health	66 ± 18	67 ± 19
	Weight	68 ± 37	69 ± 32
	Respiratory	65 ± 17	65 ± 16
	Digestion	85 ± 14	83 ± 14
	CFQ Parent	Physical	82 ± 15
Vitality		64 ± 16	74 ± 11
Emotional		79 ± 16	86 ± 13
Body		66 ± 26	78 ± 22
School		69 ± 24	72 ± 25
Eating		68 ± 30	70 ± 27
Burden		55 ± 8	59 ± 7
Health		78 ± 14	80 ± 14
Weight		61 ± 38	61 ± 38
Respiratory		73 ± 11	80 ± 11
Digestion	72 ± 21	76 ± 15	

* Plus-minus values are means ± SD. Baseline refers to the mean of the screening day and baseline day values. SF-36 = Short Form 36. CFQ = Cystic Fibrosis Questionnaire.




Figure 5. Percentage Change in FEV₁ from Baseline to 15 Minutes After Bronchodilator and 15 Minutes After Initial Dose of Allocated Trial Solution. Data points represent means and error bars represent standard deviations.

Table 5. Percentage of prescribed doses taken per quarter, determined by ampoule counts.

	NS group				HS group			
	0-12	13-24	25-36	37-48	0-12	13-24	25-36	37-48
Weeks	0-12	13-24	25-36	37-48	0-12	13-24	25-36	37-48
mean ± SD	73 ± 27	63 ± 34	63 ± 33	62 ± 36	72 ± 29	66 ± 33	61 ± 37	60 ± 38